Innovation under pressure: bold ideas for a changing malaria landscape

Innovation has never been more urgent. Encouragingly, the malaria research community is responding. Next-generation insecticide-treated nets (ITNs), new indoor residual sprays (IRS), and spatial emanators are reaching communities. Vaccines such as R21 and RTS,S are moving from trials into wider use. On the treatment front, the pipeline now includes long-lasting antimalarials, triple combination therapies (TACTs), and single-dose drugs like tafenoquine. Novel approaches such as ivermectin, recently shown to reduce malaria incidence when deployed in mass drug administration campaigns, are also gaining traction. Looking further ahead, early breakthroughs in gene drive in mosquitoes to bias inheritance of a specific genetic trait (like sterility or resistance to malaria) is passed on to offspring, and monoclonal antibodies, which point to bold new frontiers. Together, these advances represent the most significant broadening of the malaria toolkit in decades. But innovation alone will not be enough. The momentum is colliding with deep structural challenges. Funding cuts threaten to derail the rollout of new tools. Resistance is mounting: mosquitoes have developed resistance to most insecticides used for vector control, and parasites are showing reduced sensitivity to artemisinin and even lumefantrine, a key partner drug to control artemisinin resistance, in East Africa. Climate change is redrawing the risk map by shifting mosquito habitats. Health systems remain fragile, weakened by COVID-19, extreme weather, and political unrest. Even when technologies are available, their potential can be weakened by regulatory delays, fragmented governance, or inequities in access and limited community trust. The path forward requires more than breakthroughs in science. Sustained progress will depend equally on the strength of delivery systems, stable financing, and governance that can translate innovation into equitable impact.